| INTRODUCTION
Ulcerative colitis (UC) is a chronic, idiopathic, remitting and relapsing inflammatory bowel disease, usually afflicting adults of 30-40 years of age, and resulting in disability. 1 It involves the rectum, and may extend proximally in a contiguous pattern to affect part of the colon, or the entire colon. Patients experience abdominal cramps, urgency or tenesmus, fever, malaise, weight loss and fatigue, mucosal ulcers, rectal bleeding and diarrhoea, depending on the extent and severity of disease. 2 The incidence and prevalence of UC are rising over time, and in different regions around the world, indicating its emergence as a global health issue. 3 The short-term treatment goal of an active disease flare is to provide relief to the patient by reducing the severity of, or achieving resolution of, the signs and symptoms of active disease (induction phase). After this has been achieved, the long-term treatment goal is to prevent the occurrence of subsequent disease flares (maintenance phase). In both treatment phases, a related goal is to affect the disease process itself by reducing the mucosal inflammation of the colon. 4 Currently, aminosalicylates are first-line therapy for induction and maintenance of remission in active, mild-to-moderate disease;
corticosteroids are prescribed when symptoms of active colitis do not respond to aminosalicylates, while immunosuppressants and biologics are used in moderate-to-severe UC. 5, 6 Over the last decade, biological therapies have significantly improved the care of patients with UC. Infliximab was the first biologic approved for moderate-to-severe disease; then, 2 more tumour necrosis factor (TNF) antagonists, adalimumab and golimumab, and 1
anti-a4b7 antibody, vedolizumab, received regulatory approval. They have shown good efficacy and safety profiles. [7] [8] [9] Recently, tofacitinib, an oral small-molecule Janus kinase inhibitor, was shown to be more effective than placebo for induction and maintenance of remission in adults with moderate-to-severe UC. Tofacitinib is potentially a new treatment option for these patients, pending review by the US Food and Drug Administration, the European Medicines Agency and other international regulators. 10 Acquiring comparative evidence on tofacitinib and approved biologics for UC would be very useful. To this aim, we conducted a systematic review of randomised controlled trials (RCTs) assessing tofacitinib and biologics as induction and/or maintenance therapy for moderate-to-severe UC in adults. In addition to conventional metaanalytic techniques, network meta-analysis was performed, allowing for adjusted indirect treatment comparisons relative to a common comparator (placebo) and yielding estimates of comparative efficacy and harm, [11] [12] [13] based on high-quality randomised trial evidence. We aimed to provide a summary of the evidence to inform patient management decisions.
| ME TH ODS
This work was performed according to the Cochrane handbook, 14 the ISPOR network meta-analysis guidance, 15, 16 and the PRISMA statement for reporting of systematic reviews incorporating network meta-analyses. 17 
| Data sources and searches
We searched PubMed, Embase and Scopus databases through August 2017, using the following terms: tofacitinib, infliximab, adalimumab, golimumab or vedolizumab, combined with ulcerative colitis.
The search was limited to RCTs conducted in human subjects. Language restrictions were not applied. We also searched the Cochrane 
| Study selection
Titles and abstracts of the publications identified were carefully checked to exclude irrelevant studies. The full text of the selected articles was retrieved and studied. The references of these articles and other relevant systematic reviews and meta-analyses were scanned. Studies were eligible for inclusion if they were randomised, placebo-controlled or head-to-head trials assessing the efficacy and/ or harm of tofacitinib and market-authorised biologics for the treatment of adults with moderate-to-severe UC. We defined moderateto-severe UC as a Mayo Clinic score (MCS) of 6-12 points, with an endoscopic subscore of 2 or 3. MCS is a composite activity index, which is calculated as the sum of 4 items: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment.
Values can range from 0 to 12 points, with higher scores indicating more severe disease activity. 18 RCTs were eligible for inclusion irrespective of country, phase (ie 2 or 3) or source of support.
| Data extraction and risk-of-bias assessment
Two reviewers independently extracted the following information:
publication data, trial's acronym, first author's last name, geographical location of the study and year of publication, study design, number of participants, population characteristics and intervention parameters including drug, dosage and administration. We extracted only data specific for patients not previously exposed to TNF antagonists, as pooling together patients who have failed on conventional therapies and patients who have failed on TNF antagonists may result in bias in the calculation of the relative efficacy of comparator treatments. 19, 20 Different dosages of the same treatment were treated as different interventions, and for biological therapies we BONOVAS ET AL.
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We assessed the following efficacy outcomes: clinical response, clinical remission, mucosal healing, both at the end of induction and at completion of each trial's maintenance phase. Clinical response was defined as a decrease from baseline in the MCS of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or absolute rectal bleeding subscore of 0 or 1. Clinical remission was defined as a MCS of 2 points or lower, with no individual subscore exceeding 1 point. Mucosal healing was defined as absolute endoscopy subscore of 0 or 1.
Of note, with these standard definitions, it is possible that some responders may have also achieved remission, and that all remitters can also be classified as responders; there are, therefore, possible correlations between the study outcomes.
Finally, we evaluated the following adverse outcomes: number of patients with any adverse events (AEs) and number of patients with any serious adverse events (SAEs).
We investigated risk-of-bias (RoB) in included studies using the Cochrane Collaboration's tool, 21, 22 which addresses the following key domains: sequence generation; allocation concealment; blinding;
incomplete outcome data; selective outcome reporting; and other sources of bias (eg extreme baseline imbalances in prognostic factors). These particular items were classified as "low RoB," "high RoB"
or "uncertain RoB." Studies judged to be at low risk in all domains were classified as "low RoB", while those at high risk in at least 1 domain were classified as "high RoB." Disagreements among reviewers were resolved via consensus.
| Data synthesis and analysis
The odds ratio (OR) was used to measure treatment effects in all comparisons. Study-level ORs with 95% confidence intervals (CIs)
were calculated in accordance with the intention-to-treat principle.
For direct comparisons (ie vs placebo), we used fixed-effects 23 and random-effects models 24 to calculate pooled effect estimates.
Given the low-to-moderate heterogeneity detected in the analyses, fixed-effects estimates are reported in the manuscript, while both fixed-and random-effects estimates are given in forest plots.
The between-study heterogeneity was evaluated using the Cochran's Q test, 25 with a 0.10 level of significance. We also calculated the I-squared metric; 26 we considered cut-offs of <30%, 30%-59%, 60%-75% and >75% to suggest low, moderate, substantial and considerable heterogeneity. 27 On the other hand, we could not formally assess small-study effects or publication bias, given that each pairwise comparison included a limited number of studies.
In the absence of direct (ie head-to-head) comparisons of tofacitinib, adalimumab, golimumab, infliximab or vedolizumab against each other, we first examined conceptual homogeneity across trials, in terms of study designs, included populations and outcome definitions, before assessing comparative efficacy and harm with the Bucher's method of adjusted indirect comparisons. 28 According to this frequentist method, the placebo arm of each trial (ie the common comparator) is used as a "bridge" to perform a so-called "ad- ADA, adalimumab; bid, twice daily; eow, every other week; GLM, golimumab; IFX, infliximab; IV, intravenous; PO, per os; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous; TFB, tofacitinib; VDZ, vedolizumab; wk, week.
points, with an endoscopic subscore of at least 2). There were no head-to-head trials.
In most studies, patients were randomised once at the beginning of the trial, to receive either a 6-8 weeks experimental therapy or matching placebo (induction phase), often followed by a longer period during which the experimental treatments were given at maintenance schemes (maintenance phase). Of note, in 4 maintenance studies (OCTAVE Sustain; PURSUIT-J; PURSUIT-M; and GEMINI 1 maintenance) only induction responders were eligible, and were rerandomised at study beginning.
Across studies, the mean age of participants ranged between 34 and 43 years, prior disease duration from 5 to 9 years, and followup times from 6 to 54 weeks. The studies were conceptually homo- OCTAVE Induction 1; OCTAVE Induction 2; and OCTAVE Sustain), randomisation was stratified by previous exposure to TNF antagonists, and we specifically extracted only the data referring to naive patients. Thus, randomisation was maintained.
Further outcome data for the OCTAVE Induction trials were extracted from a conference abstract, 45 for the Suzuki et al study from ClinicalTrials.gov, 46 for the Study A3921063 from the EU Clinical Trials Register 47 and for the ULTRA 1 study (ITT-E population) from the US FDA website. 48 Finally, the OCTAVE Sustain trial 32 has not published any efficacy data of interest for this review regarding the subgroup of patients who were not previously exposed to TNF
antagonists.
The assessment of the RCTs, using the Cochrane Collaboration's tool, revealed low RoB across the induction trials (ACT 1; ACT 2; | 457
outcome data" domain. While follow-up was high for induction trials, equally balanced between the study groups, the rates of complete follow-up declined in maintenance phases with significant imbalances across intervention groups, and unequal drop-out rates due to AEs.
Therefore, we considered the whole group of maintenance studies as of high RoB.
T A B L E 2 Study groups and characteristics of the randomised, placebo-controlled trials in moderate-to-severe ulcerative colitis included in the networks (n = 19) F I G U R E 3 Induction of clinical remission in moderate-to-severe ulcerative colitis: forest plot. ADA, adalimumab; bid, twice daily; GLM, golimumab; IFX, infliximab; IV, intravenous; OR, odds ratio; PO, per os; SC; subcutaneous; TFB, tofacitinib; VDZ, vedolizumab RoB assessment items are shown in Figure S1 and Figure S2 for induction and maintenance studies respectively. OCTAVE Induction 1; and OCTAVE Induction 2) were incorporated in this analysis (a "star-shaped" network; Figure S3 ).
In total, 3130 anti-TNF-naive adults with moderate-to-severe UC had been randomised to placebo (n = 1386) or an experimental treatment (n = 1744; tofacitinib, adalimumab, golimumab, infliximab or vedolizumab, in dosages as in Table 1 ) as induction therapy (6-8 weeks). The estimated SUCRA values, the probabilities of each treatment being the best and the mean ranks, demonstrated that infliximab and vedolizumab rank at the top of the hierarchy of competing treatments (Table 4A for clinical response; Table 4B for clinical remission;
Direct treatment comparisons (vs placebo)
and Table 4C for mucosal healing).
| Efficacy of tofacitinib and biologics as maintenance therapy
Nine maintenance trials/phases (ACT 1; ACT 2; ULTRA 2; GEMINI 1, F I G U R E 4 Induction of mucosal healing in moderate-to-severe ulcerative colitis: forest plot. ADA, adalimumab; bid, twice daily; GLM, golimumab; IFX, infliximab; IV, intravenous; OR, odds ratio; PO, per os; SC; subcutaneous; TFB, tofacitinib; VDZ, vedolizumab PURSUIT-J) contributed to this analysis. The OCTAVE Sustain trial could not be included, as it has not yet released data regarding the subgroup of patients without previous exposure to TNF antagonists.
In total, 1776 naive patients received placebo (n = 894) or experimental treatment (n = 882; tofacitinib, adalimumab, golimumab, infliximab, or vedolizumab, in dosages as in Table 1 ) as maintenance treatment for moderate-to-severe UC.
Importantly, in 3 maintenance trials (PURSUIT-J; PURSUIT-M;
and GEMINI 1 maintenance), only induction responders were eligible, and were re-randomised at the beginning of the study. Accordingly, 
Direct treatment comparisons (vs placebo)
All evaluated treatments demonstrated superiority over placebo.
Results from individual studies and meta-analyses for maintenance of clinical response, clinical remission and mucosal healing are given in Figures S4, S5, S6 , for group A, and S7, S8, S9, for group B respectively. The column-defining drug is compared with the row-defining drug. The estimates in the cells are odd ratios (ORs) with 95% confidence intervals. For efficacy outcomes (ie clinical response, clinical remission and mucosal healing), ORs higher than 1.0 favour the treatment in the left upper square. On the opposite, for safety outcomes (AEs and SAEs), ORs higher than 1.0 correspond to harmful effects of the first drug as compared to the second drug.
T A B L E 3 Adjusted indirect treatment comparisons
To obtain ORs for comparisons in the opposite direction, reciprocals should be calculated. ADA, adalimumab; GLM, golimumab; IFX, infliximab; TFB, tofacitinib; VDZ, vedolizumab.
| Safety of tofacitinib and biologics
Safety analyses pooled data from both induction and maintenance phases. Because safety data specific for naive patients were not available for 5 of the studies having also recruited patients with prior TNF inhibitor therapy (ULTRA 2; Study A3921063; OCTAVE Induction 1; OCTAVE Induction 2; and OCTAVE Sustain), safety data for the whole randomised populations were included, instead. Overall, data from 5620 patients were synthesised (placebo, n = 2117; evaluated treatments, n = 3503).
AEs
Results from individual placebo-controlled studies and meta-analyses are given in Figure S10 Table 3D ). The corresponding SUCRA values, the estimated probabilities of each treatment being the best, as well as the comparative treatment ranks, were inconclusive (Table 4D ).
SAEs
Data from individual placebo-controlled studies and meta-analyses are shown in Figure 5 Figure 5 ). There is also indirect evidence that vedolizumab is safer than golimumab in terms of SAEs (Table 3E) .
No other indirect treatment comparison reached statistical significance. In agreement, the SUCRA values providing the hierarchy of treatments, the estimated probabilities of each treatment being the best, and the ranking of the treatments with regard to the occurrence of SAEs, indicated that vedolizumab may represent the safest option among the compared treatments (Table 4E) .
Finally, an analysis with colectomy as endpoint would be clinically useful. However, the colectomy rates were very low, when reported in the included studies. For instance, 1 colectomy was reported in the OCTAVE Induction 1 trial in a patient receiving tofacitinib 10 mg, and 1 colectomy in the OCTAVE Induction 2 trial in a patient receiving placebo, while no events of colectomy were reported in the OCTAVE Sustain trial. 32 
| DISCUSSION
In this systematic review and network meta-analysis of studies assessing tofacitinib and biological agents (infliximab, adalimumab, golimumab and vedolizumab) as induction and/or maintenance therapy for adult patients with moderate-to-severe UC and not previously exposed to TNF antagonists, evidence from 19 randomised placebo-controlled trials was synthesised. There were no head-tohead comparisons. ), and provides updated evidence to inform patient management decisions.
Our work has merits: (1) we performed an extensive and rigorous search to identify all eligible studies; (2) two authors undertook data extraction independently and discrepancies were checked and resolved; (3) studies were analysed by intention-to-treat, and potential confounders-such as age and disease duration-have been equally balanced between the arms because participants were randomly allocated; (4) induction studies included in our review are at low RoB, and allow a reliable synthesis of indirect effect estimates;
and (5) 
